SRDAN VERSTOVSEK, M.D., PHD
Osteopathic Medicine at Holcombe Blvd, Houston, TX
License number
Texas K8552
Category
Osteopathic Medicine
Type
Medical Oncology
Address
Address
1515 Holcombe Blvd, Houston, TX 77030
Phone
(713) 792-6161
(713) 792-2991
(713) 792-2991
Personal information
See more information about SRDAN VERSTOVSEK at radaris.comName
Address
Phone
Houston, TX
113 Mctighe Dr, Bellaire, TX 77401
2516A Sheridan St, Houston, TX 77030
2516 Sheridan St, Houston, TX 77030
8181 El Mundo St, Houston, TX 77054
Organization information
See more information about SRDAN VERSTOVSEK at bizstanding.comSrdan Verstovsek MD,PHD
1515 Holcombe Blvd, Houston, TX 77030
Industry:
Internist
Phone:
(713) 792-6161 (Phone)
Srdan Verstovsek
Professional information
See more information about SRDAN VERSTOVSEK at trustoria.com
Dr. Srdan Verstovsek - MD (Doctor of Medicine)
Dr. Srdan Verstovsek - MD (Doctor of Medicine)
Specialties:
Oncology, Medical Oncology
Certifications:
Internal Medicine, 1998, Medical Oncology, 2002
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
M.D. ANDERSON CANCER CENTER AT UNIVERSITY OF TEXAS
1515 Holcombe Blvd SUITE 428, Houston 77030
1515 Holcombe Blvd SUITE 207, Houston 77030
MD Anderson Cancer Center
1515 Holcombe Blvd SUITE 207, Houston 77030
Montefiore Medical Center
111 East 210Th St, Bronx 10467
Saint Joseph's Medical Center
127 South Broadway, Yonkers 10701
M.D. ANDERSON CANCER CENTER AT UNIVERSITY OF TEXAS
1515 Holcombe Blvd SUITE 428, Houston 77030
1515 Holcombe Blvd SUITE 207, Houston 77030
MD Anderson Cancer Center
1515 Holcombe Blvd SUITE 207, Houston 77030
Montefiore Medical Center
111 East 210Th St, Bronx 10467
Saint Joseph's Medical Center
127 South Broadway, Yonkers 10701
1515 Holcombe Blvd SUITE 428, Houston 77030
1515 Holcombe Blvd SUITE 207, Houston 77030
MD Anderson Cancer Center
1515 Holcombe Blvd SUITE 207, Houston 77030
Montefiore Medical Center
111 East 210Th St, Bronx 10467
Saint Joseph's Medical Center
127 South Broadway, Yonkers 10701
M.D. ANDERSON CANCER CENTER AT UNIVERSITY OF TEXAS
1515 Holcombe Blvd SUITE 428, Houston 77030
1515 Holcombe Blvd SUITE 207, Houston 77030
MD Anderson Cancer Center
1515 Holcombe Blvd SUITE 207, Houston 77030
Montefiore Medical Center
111 East 210Th St, Bronx 10467
Saint Joseph's Medical Center
127 South Broadway, Yonkers 10701
Education:
Medical School
SVEUCILISTA U ZAGREBU / MEDICAL COLLEGE
SUNY
Univ of Tex MD Anderson Cancer Center
SVEUCILISTA U ZAGREBU / MEDICAL COLLEGE
SUNY
Univ of Tex MD Anderson Cancer Center
S-Dimethylarsino-Thiosuccinic Acid S-Dimethylarsino-2-Thiobenzoic Acid S-(Dimethylarsino) Glutathione As Treatments For Cancer
S-Dimethylarsino-Thiosuccinic Acid S-Dimethylarsino-2-Thiobenzoic Acid S-(Dimethylarsino) Glutathione As Treatments For Cancer
US Patent:
7619000, Nov 17, 2009
Filed:
Feb 6, 2006
Appl. No.:
11/349043
Inventors:
Ralph A. Zingaro - College Station TX, US
Emil J. Freireich - Houston TX, US
Hatice Duzkale - Houston TX, US
Hagop Kantarjian - Bellaire TX, US
Srdan Verstovsek - Houston TX, US
Merida Sotelo-Lerma - Hermosillo, MX
Emil J. Freireich - Houston TX, US
Hatice Duzkale - Houston TX, US
Hagop Kantarjian - Bellaire TX, US
Srdan Verstovsek - Houston TX, US
Merida Sotelo-Lerma - Hermosillo, MX
Assignee:
The Texas A&M University System - College Station TX
Board of Regents, The University of Texas System - Austin TX
Board of Regents, The University of Texas System - Austin TX
International Classification:
A61K 31/285, A61K 33/36, C07F 9/00
US Classification:
514504, 556 71, 556 77, 556 78, 556 80, 424629
Abstract:
Arsenic trioxide, an inorganic compound, is commercially available anti-cancer agent but it carries significant toxicity. Organic arsenicals, on the other hand, are much less toxic, to the extent that the methylation of inorganic arsenic in vivo into organic arsenicals has been considered a detoxification reaction. New organic arsenic derivatives have been synthesized, including S-dimethylarsino-glutathione, S-dimethylarsino-thiosuccinic acid and S-dimethylarsino-thiobenzoic acid, and established its potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia. Results form a basis for the development of S-dimethylarsino-glutathione, S-dimethylarsino-thiosuccinic acid, S-dimethylarsino-thiobenzoic acid, and other organic arsenicals as an anti-cancer therapy, combining high efficacy with very low, if any, toxicity.
S-Dimethylarsino-Thiosuccinic Acid S-Dimethylarsino-2-Thiobenzoic Acid S-(Dimethylarsino) Glutathione As Treatments For Cancer
S-Dimethylarsino-Thiosuccinic Acid S-Dimethylarsino-2-Thiobenzoic Acid S-(Dimethylarsino) Glutathione As Treatments For Cancer
US Patent:
6995188, Feb 7, 2006
Filed:
Jan 13, 2005
Appl. No.:
11/035178
Inventors:
Ralph A. Zingaro - College Station TX, US
Emil J. Freireich - Houston TX, US
Hatice Duzkale - Houston TX, US
Hagop Kantarjian - Bellaire TX, US
Srdan Verstovsek - Houston TX, US
Merida Sotelo-Lerma - Hermosillo, MX
Emil J. Freireich - Houston TX, US
Hatice Duzkale - Houston TX, US
Hagop Kantarjian - Bellaire TX, US
Srdan Verstovsek - Houston TX, US
Merida Sotelo-Lerma - Hermosillo, MX
Assignee:
Board of Regents, The University of Texas System - Austin TX
The Texas A&M University System - College Station TX
The Texas A&M University System - College Station TX
International Classification:
A61K 31/285, A61K 33/36, C07F 9/70
US Classification:
514504, 556 71, 556 77, 556 78, 556 80, 424629
Abstract:
Arsenic trioxide, an inorganic compound, is commercially available anti-cancer agent but it carries significant toxicity. Organic arsenicals, on the other hand, are much less toxic, to the extent that the methylation of inorganic arsenic in vivo into organic arsenicals has been considered a detoxification reaction. New organic arsenic derivatives have been synthesized, including S-dimethylarsino-glutathione, S-dimethylarsino-thiosuccinic acid and S-dimethylarsino-thiobenzoic acid, and established its potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia. Results form a basis for the development of S-dimethylarsino-glutathione, S-dimethylarsino-thiosuccinic acid, S-dimethylarsino-thiobenzoic acid, and other organic arsenicals as an anti-cancer therapy, combining high efficacy with very low, if any, toxicity.
S-Dimethylarsino-Thiosuccinic Acid
S-Dimethylarsino-2-Thiobenzoic Acid
S-(Dimethylarsino) Glutathione As Treatments For Cancer
S-Dimethylarsino-Thiosuccinic Acid S-Dimethylarsino-2-Thiobenzoic Acid S-(Dimethylarsino) Glutathione As Treatments For Cancer
US Patent:
2008009, Apr 17, 2008
Filed:
Aug 20, 2007
Appl. No.:
11/894807
Inventors:
Ralph Zingaro - College Station TX, US
Emil Freireich - Houston TX, US
Hatice Duzkale - Houston TX, US
Hagop Kantarjian - Bellaire TX, US
Srdan Verstovsek - Houston TX, US
Merida Sotelo-Lerma - Hermosillo, MX
Emil Freireich - Houston TX, US
Hatice Duzkale - Houston TX, US
Hagop Kantarjian - Bellaire TX, US
Srdan Verstovsek - Houston TX, US
Merida Sotelo-Lerma - Hermosillo, MX
Assignee:
The Texas A&M University System - College Station TX
Board of Regents, The University of Texas System - Austin TX
Board of Regents, The University of Texas System - Austin TX
International Classification:
A61K 31/285, A61P 35/00, C07F 9/66
US Classification:
514504000, 556071000
Abstract:
Arsenic trioxide, an inorganic compound, is commercially available anti-cancer agent but it carries significant toxicity. Organic arsenicals, on the other hand, are much less toxic, to the extent that the methylation of inorganic arsenic in vivo into organic arsenicals has been considered a detoxification reaction. New organic arsenic derivatives have been synthesized, including S-dimethylarsino-glutathione, S-dimethylarsino-thiosuccinic acid and S-dimethylarsino-thiobenzoic acid, and established its potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia. Results form a basis for the development of S-dimethylarsino-glutathione, S-dimethylarsino-thiosuccinic acid, S-dimethylarsino-thiobenzoic acid, and other organic arsenicals as an anti-cancer therapy, combining high efficacy with very low, if any, toxicity.
S-Dimethylarsino-Thiosuccinic Acid S-Dimethylarsino-2-Thiobenzoic Acid S-(Dimethylarsino) Glutathione As Treatments For Cancer
S-Dimethylarsino-Thiosuccinic Acid S-Dimethylarsino-2-Thiobenzoic Acid S-(Dimethylarsino) Glutathione As Treatments For Cancer
US Patent:
2004003, Feb 19, 2004
Filed:
Jan 7, 2003
Appl. No.:
10/337969
Inventors:
Ralph Zingaro - College Station TX, US
Emil Freireich - Houston TX, US
Hatice Duzkale - Houston TX, US
Hagop Kantarjian - Bellaire TX, US
Srdan Verstovsek - Houston TX, US
Merida Sotelo-Lerma - Hermosillo, MX
Emil Freireich - Houston TX, US
Hatice Duzkale - Houston TX, US
Hagop Kantarjian - Bellaire TX, US
Srdan Verstovsek - Houston TX, US
Merida Sotelo-Lerma - Hermosillo, MX
International Classification:
A61K031/285, C07F009/70
US Classification:
514/504000, 556/069000
Abstract:
Arsenic trioxide, an inorganic compound, is commercially available anti-cancer agent but it carries significant toxicity. Organic arsenicals, on the other hand, are much less toxic, to the extent that the methylation of inorganic arsenic in vivo into organic arsenicals has been considered a detoxification reaction. New organic arsenic derivatives have been synthesized, including S-dimethylarsino-glutathione, S-dimethylarsino-thiosuccinic acid and S-dimethylarsino-thiobenzoic acid, and established its potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia. Results form a basis for the development of S-dimethylarsino-glutathione, S-dimethylarsino-thiosuccinic acid, S-dimethylarsino-thiobenzoic acid, and other organic arsenicals as an anti-cancer therapy, combining high efficacy with very low, if any, toxicity.
Compounds And Methods For The Treatment Of Cancer
Compounds And Methods For The Treatment Of Cancer
US Patent:
7405314, Jul 29, 2008
Filed:
Oct 17, 2005
Appl. No.:
11/252966
Inventors:
Ralph A. Zingaro - College Station TX, US
Hatice Duzkale - Houston TX, US
Emil J. Freireich - Houston TX, US
Hagop Kantarjian - Bellaire TX, US
Merida Sotelo-Lerma - Hermosillo, MX
Srdan Verstovsek - Houston TX, US
Mingzhang Gao - Indianapolis IN, US
Hatice Duzkale - Houston TX, US
Emil J. Freireich - Houston TX, US
Hagop Kantarjian - Bellaire TX, US
Merida Sotelo-Lerma - Hermosillo, MX
Srdan Verstovsek - Houston TX, US
Mingzhang Gao - Indianapolis IN, US
Assignee:
The Texas A&M University System - College Station TX
Board of Regents, The University of Texas System - Austin TX
Board of Regents, The University of Texas System - Austin TX
International Classification:
A61K 61/285, C07F 9/00
US Classification:
556 71, 556 76, 514504
Abstract:
The present invention provides organic arsenicals. Many of these compounds have potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia.
Compounds And Methods For The Treatment Of Cancer
Compounds And Methods For The Treatment Of Cancer
US Patent:
2008009, Apr 17, 2008
Filed:
Aug 20, 2007
Appl. No.:
11/894766
Inventors:
Ralph Zingaro - College station TX, US
Hatice Duzkale - Houston TX, US
Emil Freireich - Houston TX, US
Hagop Kantarjian - Bellaire TX, US
Merida Sotelo-Lerma - Hermosillo, MX
Srdan Verstovsek - Houston TX, US
Mingzhang Gao - Indianapolis IN, US
Hatice Duzkale - Houston TX, US
Emil Freireich - Houston TX, US
Hagop Kantarjian - Bellaire TX, US
Merida Sotelo-Lerma - Hermosillo, MX
Srdan Verstovsek - Houston TX, US
Mingzhang Gao - Indianapolis IN, US
Assignee:
The Texas A&M University System - College Station TX
Board of Regents, The University of Texas System - Austin TX
Board of Regents, The University of Texas System - Austin TX
International Classification:
A61K 31/285, A61K 31/555, A61P 35/00, C07F 9/00, C07F 9/80
US Classification:
514188000, 514504000, 546003000, 556070000
Abstract:
The present invention provides organic arsenicals. Many of these compounds have potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia.
Pharmaceutical Combinations And Methods For The Treatment Of Leukemia
Pharmaceutical Combinations And Methods For The Treatment Of Leukemia
US Patent:
2004019, Sep 30, 2004
Filed:
Dec 8, 2003
Appl. No.:
10/729387
Inventors:
Francis Giles - Houston TX, US
Srdan Verstovsek - Houston TX, US
Srdan Verstovsek - Houston TX, US
International Classification:
A61K031/675, A61K031/513
US Classification:
514/081000, 514/269000, 514/085000
Abstract:
In accordance with the present invention there is provided a pharmaceutical combination useful for the treatment of leukemia comprising at least one active compound of formula (I):
and a Bcr-Abl tyrosine kinase inhibitor, and a method of treating a patient having leukemia comprising at least one active compound of formula (I), as defined above, and a Bcr-Abl tyrosine kinase inhibitor.